PATH
Population Assessment
of Tobacco and Health
A collaboration between the NIH and FDA

Survey Introduction

The Population Assessment of Tobacco and Health (PATH) Study, a collaboration between the NIH National Institute on Drug Abuse and FDA Center for Tobacco Products, would like to learn more about your experiences with the PATH Study and what we can do better.

If you experience difficulties accessing the survey or have questions about it, please contact nahdap@icpsr.umich.edu.

For text options, we recommend typing the sentences in a word processor (e.g. MS Word) and copying and pasting in the text box. Please click the next arrow button below to get started.

→

Access and use of PATH Study data

Where have you received information about the PATH Study data? (please select all that apply)

☐ Google or other search engines

☐ Participated in a webinar or in-person training

☐ Conference exhibit/brochure

☐ Word of mouth/from a colleague

☐ Through research papers/publications

☐ Other (please specify, 1000 character limit):

☐ I have never heard of the PATH Study.

←   →

PATH
Population Assessment
of Tobacco and Health

A collaboration between the NIH and FDA

Please pick one category that best describes your organizational affiliation:

○ College or university

○ Research contract organization

○ Commercial/industry (please provide type of industry):

○ Non-profit organization

○ Government

○ Hospital/healthcare organization

○ Other (please specify, 1000 character limit):

○ No organizational affiliation

←   →

Which of the following PATH Study data set(s) have you previously used or analyzed (select all that apply):

☐ Restricted-Use Files (RUF)

☐ Public-Use Files (PUF)

☐ Biomarker Restricted-Use Files (BRUF)

☐ Special Collection Restricted-Use Files (SCRUF)

☐ Special Collection Public-Use Files (SCPUF)

☐ State Indicator Restricted-Use Files (SIRUF)

☐ Tobacco Universal Product Code Restricted-Use Files (TUPCRUF)

☐ None

← →

PATH
Population Assessment
of Tobacco and Health
A collaboration between the NIH and FDA

PATH Study data was used/will be used to inform _____ (select all that apply):

☐ Academic research supporting research project goals, publication, or presentation

☐ Exploratory research to support research proposals and/or funding applications

☐ Policy-making

☐ Thesis or dissertation

☐ Research for a class project

☐ Teaching/instruction

☐ Marketing or campaign development

☐ Industry applications

☐ Regulatory documents

☐ Social media content

☐ Other (please specify, 1000 character limit):

[   ]

How many years of experience have you had using or analyzing existing PATH Study data?

○ Less than one year

○ 1-2 years

○ 3-4 years

○ 5 years or more

PATH
Population Assessment
of Tobacco and Health
A collaboration between the NIH and FDA

Please select the best response from the statements below about your experiences accessing and downloading the PATH Study data.

	Strongly agree	Agree	Neither agree nor disagree	Disagree	Strongly disagree
Restricted-Use Files (RUF) are easy to find on the NAHDAP website.	○	○	○	○	○
Public-Use Files (PUF) are easy to access and download on the NAHDAP website.	○	○	○	○	○
Biomarker Restricted-Use Files (BRUF) are easy to find on the NAHDAP website.	○	○	○	○	○
Special Collection Restricted-Use Files (SCRUF) are easy to find on the NAHDAP website.	○	○	○	○	○
Special Collection Public-Use Files (SCPUF) are easy to access and download on the NAHDAP website.	○	○	○	○	○
State Indicator Restricted-Use Files (SIRUF) are easy to find on the NAHDAP website.	○	○	○	○	○
Tobacco Universal Product Code Restricted-Use Files (TUPCRUF) are easy to find on the NAHDAP website.	○	○	○	○	○

Think about the experience you had finding, accessing and downloading the PATH Study data. Please list any suggestions you have for improving the accessibility of the PATH Study data (1000 character limit).

Characters remaining: 1000

Please select the best response from the statements below about your experiences structuring and preparing the PATH Study data for use.

	Strongly agree	Agree	Neither agree nor disagree	Disagree	Strongly disagree
Restricted-Use Files (RUF) data set is easy to structure and prepare for data analysis.	○	○	○	○	○
Public-Use Files (PUF) data set is easy to structure and prepare for data analysis.	○	○	○	○	○
Biomarker Restricted-Use Files (BRUF) data set is easy to structure and prepare for data analysis.	○	○	○	○	○
Special Collection Restricted-Use Files (SCRUF) data set is easy to structure and prepare for data analysis.	○	○	○	○	○
Special Collection Public-Use Files (SCPUF) data set is easy to structure and prepare for data analysis.	○	○	○	○	○
State Indicator Restricted-Use Files (SIRUF) data set is easy to structure and prepare for data analysis.	○	○	○	○	○
Tobacco Universal Product Code Restricted-Use Files (TUPCRUF) data set is easy to structure and prepare for data analysis.	○	○	○	○	○

Think about the experience you had structuring and preparing the PATH Study data. Please list any comments or suggestions you have in response to your experience structuring and preparing the PATH Study data for use (1000 character limit).

Characters remaining: 1000

PATH
Population Assessment
of Tobacco and Health
A collaboration between the NIH and FDA

To what extent did these datasets meet your intended needs?

	Met needs exactly	Met needs partially	Did not meet needs at all
Restricted-Use Files (RUF)	○	○	○
Public-Use Files (PUF)	○	○	○
Biomarker Restricted-Use Files (BRUF)	○	○	○
Special Collection Restricted-Use Files (SCRUF)	○	○	○
Special Collection Public-Use Files (SCPUF)	○	○	○
State Indicator Restricted-Use Files (SIRUF)	○	○	○
Tobacco Universal Product Code Restricted-Use Files (TUPCRUF)	○	○	○

← →

![PATH - Population Assessment of Tobacco and Health. A collaboration between the NIH and FDA]

Have you experienced any issues within the Virtual Data Enclave (VDE)? (Select all that apply)

☐ Limited space

☐ Capacity of statistical software

☐ Access to the VDE

☐ Navigating the application/project in the VDE

☐ Managing interface

☐ Disclosure review process

☐ Other (please describe, 1000 character limit):

☐ No issues

What would be/is the statistical software you use for your data analyses in the VDE? (select all that apply)

☐ MPlus

☐ R

☐ SAS

☐ SPSS

☐ Stata

☐ SUDAAN

☐ Other (please name, 1000 character limit):

← →

PATH
Population Assessment
of Tobacco and Health
A collaboration between the NIH and FDA

Training and Support Needs

How useful are the following PATH Study training tools and resources? (select the response from very useful to not useful at all)

	Very useful	Somewhat useful	Not useful at all	Don't know/Never used or attended it
PATH Study Data User Guides	○	○	○	○
PATH Study Summer Workshops hosted by NAHDAP/University of Michigan	○	○	○	○
PATH Study Data User Forum	○	○	○	○
Researcher query portal through which PATH Study data users can submit their questions via *PATHDataUserQuestions@Westat.com*	○	○	○	○
PATH Study 101 Webinar that can be accessed through NAHDAP's PATH Study Series Page	○	○	○	○

Are there any topics you think should be added to or further expanded on in the PATH Study Data User Guide?

○ Yes
   If yes, please specify (1000 character limit):

○ No

○ Don't know

Please list any comments or suggestions you have for improving the trainings, user support, or other resources available to PATH Study data users (1000 character limit).

Characters remaining: 1000

←   →

Behavioral Data

Please provide your suggestions for research topics _NOT_ currently captured by the PATH Study that could be included in the future to inform tobacco regulatory science (1000 character limit).

Characters remaining: 1000

Please provide suggestions for survey questions that should be added to the PATH Study survey instrument in the future. If possible, please provide more details, including sources or recommended items and information on whether those items have been validated (1000 character limit).

Characters remaining: 1000

Are you interested in using PATH Study biospecimens and/or analyzing PATH Study biomarker data in the future?

○ Yes

○ No

←   →

Biospecimens

Please share your thoughts about the frequency of biospecimen collection in the PATH Study.

Urine is currently collected among a subsample of participants during the full cohort data collection (Waves 1-5). Does the current frequency of biospecimen collections of urine meet your needs?

○ Yes

○ No

○ Don't know

←   →

PATH
Population Assessment
of Tobacco and Health
A collaboration between the NIH and FDA

How frequently (in years) do you recommend collection of *urine* biospecimens from respondents for longitudinal analysis?

[   ]

← →

PATH
Population Assessment
of Tobacco and Health
A collaboration between the NIH and FDA

Blood has been collected less frequently than urine, with the majority of the blood collections occurring in Wave 1. Does the current frequency of biospecimen collections of blood meet your needs?

○ Yes

○ No

○ Don't know

← →

PATH
Population Assessment
of Tobacco and Health
A collaboration between the NIH and FDA

How frequently (in years) do you recommend collection of *blood* biospecimens from respondents for longitudinal analysis?

[   ]

← →

Biomarker Data

The PATH Study collects a variety of biomarkers; please click here to view a current list of biomarkers that have been analyzed in the PATH Study. Please provide your recommendations for additional biomarkers or groups/classes of biomarkers (1000 character limit).

Characters remaining: 1000

Please provide additional comments or suggestions on the PATH Study biomarker data availability and analysis (1000 character limit).

Characters remaining: 1000

Are you aware of the PATH Biospecimen Access Program?

◯ No

◯ Yes, and have applied or may apply in the future

◯ Yes, but not intending to apply to the program

PATH
Population Assessment
of Tobacco and Health
A collaboration between the NIH and FDA

Biospecimen Access Program

How did you first hear about the PATH Study Biospecimen Access Program?

○ From colleagues or professors

○ Conference

○ ICSR/NAHDAP website

○ From professional organization or list serv

○ Other (please specify, 1000 character limit):

Please share any suggestions for improving awareness of the Biospecimen Access Program, including any professional organizations that would benefit from knowing about the Biospecimen Access Program (1000 character limit).

Characters remaining: 1000

Please share why you do not intend to apply to the Biospecimen Access Program (1000 character limit).

Characters remaining: 1000

Please select the best response from the statements below about the Biospecimen Access Program's proposal process and descriptions.

	Strongly agree	Agree	Neither agree nor disagree	Disagree	Strongly disagree	Don't know/ No opinion
The proposal process for submission to the Biospecimen Access Program is clear and straighforward.	○	○	○	○	○	○
The selection/evaluation criteria are clear and easy to understand.	○	○	○	○	○	○
The Biospecimen Access Program process seems too burdensome.	○	○	○	○	○	○

Please provide any additional feedback about the Biospecimen Access Program proposal process (1000 character limit).

Characters remaining: 1000

←   →

PATH
Population Assessment
of Tobacco and Health
A collaboration between the NIH and FDA

We welcome your input!

**Please contact us at nahdap@icpsr.umich.edu
if you would like to provide additional feedback about the PATH Study.**

Thank you for completing the survey!